688670 Jiangsu Gdk Biological Technology
- 17.50
- +0.59+3.49%
Jiangsu Gdk Biological Technology News
Jindick (688670.SH): Net loss of 21.494 million yuan in the first quarter
On April 15, Ge Longhui (688670.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 50,181 million yuan, a year-on-year decrease of 95.28%; net profit attributable to shareholders of listed companies - 21.494 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 244.23,500 yuan; and basic earnings per share - 0.17 yuan.
Jindick (688670.SH) reported 2023 annual results, with a net loss of 70.993 million yuan, which changed from profit to loss over the previous year
According to Zhitong Finance App News, Jindick (688670.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 135 million yuan, a year-on-year decrease of 57.74%; net loss attributable to shareholders of listed companies was 72.503 million yuan, which changed from profit to loss; net loss attributable to shareholders of listed companies was deducted from non-recurring profit and loss of 72.579 million yuan, year-on-year from profit to loss; basic loss per share was 0.58 yuan/share. During the reporting period, operating revenue decreased by 57.74% compared to the same period last year, mainly due to the temporary suspension of production due to a sudden heavy rain in Taizhou, where the company is located in July 2023, until
Kindick (688670.SH): Net loss of 657.796 million yuan in 2023
On February 23, Ge Longhui (688670.SH) announced the 2023 annual results report. The company achieved operating income of 139.659 million yuan in 2023, a year-on-year decrease of 56.05%; realized net profit attributable to the owner of the parent company - 657.796 million yuan, a year-on-year decrease of 258.34%; realized net profit attributable to the owner of the parent company after deducting non-recurring gains and losses - 74.51 million yuan, a year-on-year decrease of 429.42%.
More Unpleasant Surprises Could Be In Store For Jiangsu Gdk Biological Technology Co., Ltd's (SHSE:688670) Shares After Tumbling 27%
Unfortunately for some shareholders, the Jiangsu Gdk Biological Technology Co., Ltd (SHSE:688670) share price has dived 27% in the last thirty days, prolonging recent pain. The drop over the last 3
Kindick (688670.SH) issued a forecast loss and is expected to have a net loss of 65 million yuan in 2023
Kindick (688670.SH) released its 2023 annual performance forecast, which is expected to generate revenue for the full year of 2023...
Kindick (688670.SH): The freeze-dried human rabies vaccine (Vero cells) is being declared to the national CDE in accordance with the procedure
On January 23, Ge Longhui (688670.SH) said on the investor interactive platform that the company's freeze-dried human rabies vaccine (Vero cells) is being reported to the national CDE in accordance with the procedures. Due to the strict science of registration of the new drug, the review cycle is long, so stay tuned for further progress.
Some Confidence Is Lacking In Jiangsu Gdk Biological Technology Co., Ltd (SHSE:688670) As Shares Slide 26%
Jiangsu Gdk Biological Technology Co., Ltd (SHSE:688670) shareholders won't be pleased to see that the share price has had a very rough month, dropping 26% and undoing the prior period's positive perf
Kim Dick (688670.SH): “New quadrivalent influenza virus lysis workshop project” and innovative vaccine research and development project postponed
On December 25, Gelonghui (688670.SH) announced that the equipment for the “New Quadrivalent Influenza Virus Cracking Workshop Project” has all been put in place, and several rounds of commissioning have been carried out in the early stages. It was originally planned to reach the intended useable state in January 2024. Later, due to the external epidemic, the temporary shutdown of the company, etc., the project commissioning and verification work lagged behind the original plan. A new round of debugging and verification was needed. GMP verification and drug administration department inspection are lagging behind the original plan. While the investment content, total investment amount, and implementation entity of the fund-raising project remain unchanged, it was decided, after scientific evidence, that the fund-raising project would “build a new four-price model”
Kim Dick (688670.SH): The influenza vaccine market is not a stock game, but an incremental competition
Glonghui December 19|Kim Dick (688670.SH) said on the investor interactive platform that the influenza vaccine market is not a stock game, but an incremental competition. What is significantly different from other vaccines is that the influenza vaccine is given every year and covers people of all ages. The market space is large and demand is stable, so companies in the industry are developing quadrivalent influenza vaccines one after another to expand production capacity. We know that the vaccine has a large investment in R&D (8 to 1 billion yuan) and a long cycle (8-10 years). The increase in entrants shows the industry's confidence in future market growth from another side. Competition within the influenza vaccine industry is not a stock boom
Kim Dick (688670.SH): Currently, the domestic influenza vaccination rate is very low, far below the 50% vaccination rate in Europe and the US and 20%-30% in East Asia
GLONGHUI December 19丨Kim Dick (688670.SH) said on the investor interactive platform that there is broad room for growth in the influenza vaccine market. Currently, the domestic influenza vaccination rate is very low, far below the 50% vaccination rate in Europe and the US and 20%-30% in East Asia. Compared with the 75% target influenza vaccination rate recommended by the World Health Organization for key population groups, the current vaccination rate for key population groups in China is less than 5%, yet the key population in Europe, America, and other regions of East Asia has exceeded 60%. The key population base for children under 18 and people aged 60 and above in China is about 517 million, and the overall vaccination rate for key population groups is also very low
Kim Dick (688670.SH): The quadrivalent influenza vaccine for the 2023-2024 influenza season was issued in batches
GLONGHUI December 19丨Jindick (688670.SH) announced that as of the disclosure date of this announcement, a total of 8 batches of the company's quadrivalent influenza vaccine for the 2023-2024 influenza season have been issued by the Central Inspection Institute and can be marketed. The company is selling and delivering goods to the market in an orderly manner to meet people's influenza vaccination needs. However, we are now nearing the end of sales for the 2023-2024 influenza season, and there is still uncertainty about the specific product sales situation.
Guolian Securities: Respiratory infectious diseases combined with high incidence seasons are optimistic about investment opportunities in the diagnosis and treatment industry chain
Vaccines are the most effective means of preventing infectious diseases, and the high incidence of influenza is expected to accelerate the release of demand for vaccination.
Kim Dick (688670.SH): The company's freeze-dried human rabies vaccine (Vero cells) has completed phase III clinical trials and obtained clinical summary reports
Gelonghui, November 24|Kim Dick (688670.SH) said on the investor interactive platform that the company's freeze-dried human rabies vaccine (Vero cells) has completed phase III clinical trials and obtained clinical summary reports. Due to the strict science of new drug registration and a long review cycle, the company is reporting to the national CDE in accordance with the procedures.
[BT Financial Report Instantaneous Analysis] Jindick's 2023 Quarterly Report: Operating income and net profit declined, and net cash flow increased significantly
This financial report was announced on 2023-10-27 16:26:03 Jiangsu Jindike Biotechnology Co., Ltd. (stock code: 688670) is an enterprise focusing on R&D, production and sales of human vaccines. Its main products include human vaccines to prevent infectious diseases such as influenza, rabies, chicken pox, shingles, and pneumonia. The company has marketed a quadrivalent influenza virus lysis vaccine. The vaccine is superior to the standards of the Chinese Pharmacopoeia and European Pharmacopoeia in terms of immune efficacy and safety. In terms of assets and liabilities, the total assets of Jindik at the end of the third quarter of 2023 are
Should Weakness in Jiangsu Gdk Biological Technology Co., Ltd's (SHSE:688670) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
It is hard to get excited after looking at Jiangsu Gdk Biological Technology's (SHSE:688670) recent performance, when its stock has declined 14% over the past week. But if you pay close attention, y
Kim Dick (688670.SH): 1,232 million restricted shares lifted on August 2
On July 25, GLONGHUI|JINDECK (688670.SH) announced that the total number of shares listed and circulated by the company is 1,232 million shares, and the stock listing and circulation date is August 2, 2023.
“20CM” came to a standstill! The plant was flooded and production was temporarily stopped, and the vaccine factory warned that Q3 revenue may be 0
Performance declined for two consecutive years
Taizhou torrential rain A-share impact tracking: Jindick may have “no grain collection”, and the responses of more than 10 listed companies have no impact
The extreme weather during the typhoon season is having a potential impact on the production and operation activities of some listed companies. On July 17, the Taizhou Meteorological Observatory issued an orange warning signal for rainstorms, initiating a level-IV emergency response for flood control. Prior to that, beginning on July 6, rare heavy rain began to occur in the north-central region of the region. Whether this will adversely affect local companies is receiving market attention. According to Wind data, a total of 16 A-share companies have registered addresses in Taizhou. Some local companies have issued announcements confirming that production and operation have been impacted. On July 15, influenza vaccine company Kim Dick (688670.SH
Impacted by torrential rain: Kim Dick's revenue for the third quarter is likely to return to zero, and it has already fallen to a halt by 20cm intraday
A torrential rain in Taizhou, Jiangsu thundered Jin Dick (688670.SH), a company listed on the A-share Science and Technology Innovation Board. On July 14, Jindik issued an announcement stating that due to heavy rain in the Taizhou Pharmaceutical High-tech Zone (Gaogang District) where the company is located, the company's plant was flooded, and the production environment in some workshops was affected by water seepage. After continuous environmental monitoring and comprehensive assessment, the company decided to temporarily stop production of the influenza vaccine workshop on July 15. Kim Dick said that all of the company's revenue comes from the quadrivalent influenza vaccine. The production and sales of influenza vaccines have obvious seasonal characteristics. Every year, September-December is the peak season for influenza vaccine sales. Because of the flow
Jiangsu Gdk Biotechnology Co., Ltd.'s (SHSE:688670) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
It is hard to get excited after looking at Jiangsu gdk Biotechnology's (SHSE:688670) recent performance, when its stock has declined 27% over the past month. However, stock prices are usually driven
Analysis
Price Target
No Data
